Evidence map›Paper›PMID 41575601›Full record

ArticleJournal of neuro-oncology2026

PET RANO 1.0 criteria improve prognostic stratification in high-grade gliomas using

Shih-Hsin Chen, Hsin-Ning Wang, Cheng Hong Toh, Kuo-Chen Wei, Ko-Ting Chen, Chen-Kan Tseng, Kung-Chu Ho

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shih-Hsin ChenDepartment of Nuclear Medicine, Linkou Chang Gung Memorial Hospital, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
Hsin-Ning WangDepartment of Nuclear Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
Cheng Hong TohDepartment of Diagnostic Radiology and Intervention, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
Kuo-Chen WeiDepartment of Neurosurgery, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
Ko-Ting ChenDepartment of Neurosurgery and Neuroscience Research Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
Chen-Kan TsengDepartment of Radiation Oncology, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
Kung-Chu HoDepartment of Nuclear Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan. b8301068@gmail.com.

Funding

Chang Gung Memorial Hospital CMRPG2I0151
6 · The paper itself

Abstract

purposeThis study aimed to identify prognostic factors for survival outcomes in patients with high-grade gliomas (HGGs) using 11C-methionine positron emission tomography/magnetic resonance imaging (MET PET/MR) to evaluate tumor response following surgical resection and concurrent chemoradiotherapy (CCRT).

methodsTwenty-nine patients with histologically confirmed grade 3 and 4 HGGs were enrolled between November 2019 and May 2022. All patients underwent baseline MET PET/MR scans within one month post-surgery, followed by standard Stupp protocol chemoradiotherapy. Twenty-three patients completed follow-up scans post-CCRT. Treatment response was evaluated using PET RANO 1.0 criteria for PET, and RANO 2.0 criteria for MRI. Prognostic factors were analyzed using Cox proportional hazards models.

resultsAmong 23 patients evaluated post-CCRT, PET RANO 1.0 classified 18 as responders and 5 as non-responders. PET responders demonstrated significantly superior median progression-free survival (PFS) (22.4 vs. 4.0 months, P < 0.001) and overall survival (OS) (47.9 vs. 11.4 months, P < 0.001) compared with non-responders. Conversely, MRI RANO 2.0 criteria did not show statistically significant differences in survival outcomes (median PFS: 20.9 vs. 9.2 months, P = 0.510; median OS: 44.0 vs. 17.3 months, P = 0.902). Multivariate analysis confirmed MET PET response as an independent prognostic factor for both PFS and OS.

conclusionsMET PET response assessment based on PET RANO 1.0 criteria demonstrated potential prognostic utility, offering complementary information to conventional MRI-based assessment.

Indexed as

Brain NeoplasmsGliomaMagnetic Resonance ImagingPositron-Emission TomographyAdultAgedCarbon RadioisotopesChemoradiotherapyFemaleFollow-Up StudiesHumansMaleMethionineMiddle AgedMultimodal ImagingNeoplasm GradingCarbon RadioisotopesMethionineRadiopharmaceuticals11C-methionineHigh-grade gliomasPET/MRPET RANO 1.0

Identifiers

PMID41575601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.